DESCRIPTION (provided by applicant): Aging is characterized by progressive, degenerative changes in many organ systems. These changes result in significant functional declines in elderly people and often contribute to death. Treatments that delay age- related degeneration would be desirable, but few are available. The long-term objective of this proposal is to identify drugs that can delay age-related degeneration. This proposal exploits nematode worms and mice as model systems to analyze aging. Nematodes are a powerful experimental system that is convenient for genetic, molecular, and pharmacologic studies, whereas mice are highly relevant to humans. The preliminary studies describe the identification of FDA-approved drugs that can extend the adult lifespan of worms including ethosuximide, trimethadione and valproic acid. Specific aim 1 proposes to characterize the mechanism of action of valproic acid by testing the hypothesis that valproic acid functions as an inhibitor of histone deacetylases. In addition, the hypothesis that ethosuximide and trimethadione function by modulating neural activity will be tested by analyzing mutants that are resistant to these drugs. A detailed, mechanistic understanding of the action of these drugs is important because it will elucidate endogenous pathways that influence aging, and establish a foundation for considering the therapeutic use of these drugs. Specific aim 2 proposes to identify FDA-approved drugs that can extend worm lifespan and characterize the mechanism of action of these drugs. The identification of drugs that delay aging is significant for two reasons. First, it might lead to the identification of new mechanisms that influence aging. Second, because these drugs are approved for human use, these studies might lead to therapies that can delay age-related degenerative changes in humans. Specific aim 3 proposes to determine if trimethadione and valproic acid can extend the lifespan of mice or delay age-related changes. The demonstration that these FDA-approved drugs delay aging in a vertebrate would be significant.
Public Health Relevance Statement
Data not available.
NIH Spending Category
Aging**
Project Terms
AdultAffectAgingAnticonvulsantsBiological ModelsCessation of lifeClassDrug effect disorderDrug resistanceElderlyEthosuximideFoundationsHistonesHumanLarvaLeadLens OpacitiesLongevityMolecular GeneticsMovementMusNematodaPathway interactionsPharmaceutical PreparationsRateResistanceStressStructureSystemTestingTherapeutic UsesTrimethadioneValproic AcidVertebratesage relatedbody systemfunctional declineinhibitor/antagonistmutantnovelnovel strategiesrelating to nervous system
No Sub Projects information available for 5R01AG026561-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AG026561-03
Patents
No Patents information available for 5R01AG026561-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AG026561-03
Clinical Studies
No Clinical Studies information available for 5R01AG026561-03
News and More
Related News Releases
No news release information available for 5R01AG026561-03
History
No Historical information available for 5R01AG026561-03
Similar Projects
No Similar Projects information available for 5R01AG026561-03